Biomedical Engineering Reference
In-Depth Information
not increased in chronic obstructive pulmonary disease [see comments].
Thorax 1999; 54:576-580.
39. Corradi M, Majori M, Cacciani GC, Consigli GF, de'Munari E, Pesci A.
Increased exhaled nitric oxide in patients with stable chronic obstructive
pulmonary disease. Thorax 1999; 54:572-575.
40. Agusti AG, Villaverde JM, Togores B, Bosch M. Serial measurements of
exhaled nitric oxide during exacerbations of chronic obstructive pulmonary
disease. Eur Respir J 1999; 14:523-528.
41. Corradi M, Montuschi P, Donnelly LE, Pesci A, Kharitonov SA, Barnes PJ.
Increased nitrosothiols in exhaled breath condensate in inflammatory airway
diseases. Am J Respir Crit Care Med 2001; 163:854-858.
42. Kanazawa H, Shiraishi S, Hirata K, Yoshikawa J. Imbalance between levels
of nitrogen oxides and peroxynitrite inhibitory activity in chronic obstructive
pulmonary disease. Thorax 2003; 58:106-109.
43. Barnes PJ, Ito K, Adcock IM. A mechanism of corticosteroid resistance in
COPD: inactivation of histone deacetylase. Lancet 2004, in press.
44. Chalmers GW, Macleod KJ, Sriram S, Thomson LJ, McSharry C, Stack BH,
et al. Sputum endothelin-1 is increased in cystic fibrosis and chronic obstruc-
tive pulmonary disease. Eur Respir J 1999; 13:1288-1292.
45. Roland M, Bhowmik A, Sapsford RJ, Seemungal TA, Jeffries DJ, Warner
TD, et al. Sputum and plasma endothelin-1 levels in exacerbations of chronic
obstructive pulmonary disease. Thorax 2001; 56:30-35.
46. Trakada G, Marangos M, Spiropoulos K. Mechanisms of endothelin-1 eleva-
tion in chronic obstructive pulmonary disease patients with nocturnal oxyhe-
moglobin desaturation. Respiration 2001; 68:134-139.
47. Spiropoulos K, Trakada G, Nikolaou E, Prodromakis E, Efremidis G, Pouli
A, et al. Endothelin-1 levels in the pathophysiology of chronic obstructive
pulmonary disease and bronchial asthma. Respir Med 2003; 97:983-989.
48. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib M, et al.
Expression of endothelin-1 in the lungs of patients with pulmonary hyperten-
sion. New Engl J Med 1993; 328:1732-1739.
49. Barnes PJ. Bradykinin and asthma. Thorax 1992; 47:979-983.
50. Haddad EB, Fox AJ, Rousell J, Burgess G, McIntyre P, Barnes PJ, et al. Post-
transcriptional regulation of bradykinin B
1
and B
2
receptor gene expression in
human lung fibroblasts by tumor necrosis factor-a: modulation by dexametha-
sone. Mol Pharmacol 2000; 57:1123-1131.
51. Tsukagoshi H, Haddad E-B, Barnes PJ, Chung KF. Bradykinin receptor
subtypes in rat lung: effect of interleukin-lb. J Pharmacol Exp Ther 1995;
273:1257-1263.
52. Trevisani M, Schmidlin F, Tognetto M, Nijkamp FP, Gies JP, Frossard N, et
al. Evidence for in vitro expression of B
1
receptor in the mouse trachea and
urinary bladder. Br J Pharmacol 1999; 126:1293-1300.
53. Hulsmann AR, Raatgep R, Saxena PR, Kerrebijn KF, de Jongste JC.
Bradykinin-induced contraction of human peripheral airways mediated by
both bradykinin B
2
and thromboxane receptors. Am J Respir Crit Care
Med 1994; 150:1012-1018.
